Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dopamine therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    117 result(s) found for: Dopamine therapy. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2019-004880-33 Sponsor Protocol Number: 18F-FDOPA-BUP-ESC Start Date*: 2023-01-20
    Sponsor Name:Medical University of Vienna, University Department of Psychiatry and Psychotherapy
    Full Title: Reward-specific changes of cerebral dopamine synthesis in healthy volunteers and depressed patients
    Medical condition: Major Depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001485-41 Sponsor Protocol Number: AMAD001 Start Date*: 2005-04-20
    Sponsor Name:Institute for Neurodegenerative Disorders
    Full Title: A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease
    Medical condition: Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see exclusionary criteria).
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: AT (Completed) GB (Prematurely Ended) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003131-38 Sponsor Protocol Number: DOPA2016 Start Date*: 2017-06-23
    Sponsor Name:TARGID, KU Leuven
    Full Title: The effect of chlorpromazine (Largactil), a dopamine type 2-(D2-) receptor antagonist, on esophageal sensitivity in healthy volunteers: a randomized, double-blind, placebo-controlled study
    Medical condition: Increased esophageal sensitivity in refractory gastro-esophageal reflux disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004146-88 Sponsor Protocol Number: 27938 Start Date*: 2009-05-19
    Sponsor Name:Newron Pharmaceuticals
    Full Title: A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subject...
    Medical condition: Idiopathic Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) PT (Completed) ES (Completed) IT (Completed) SK (Completed) BG (Completed) PL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002963-28 Sponsor Protocol Number: 27918 Start Date*: 2007-12-12
    Sponsor Name:Newron Pharmaceuticals SpA
    Full Title: A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects wit...
    Medical condition: Idiopathic Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) ES (Completed) IT (Completed) SK (Completed) PT (Completed) PL (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005701-22 Sponsor Protocol Number: Droxidopa-303 Start Date*: 2009-04-13
    Sponsor Name:Chelsea Therapeutics Inc
    Full Title: A MULTI-CENTER, OPEN-LABEL STUDY, WITH A TWO WEEK RANDOMIZED, PLACEBO-CONTROLLED, WITHDRAWAL PERIOD, TO ASSESS THE LONG-TERM SAFETY AND CLINICAL BENEFIT OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONO...
    Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (PD, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001148-31 Sponsor Protocol Number: Start Date*: 2011-09-13
    Sponsor Name:Imperial College London
    Full Title: A pilot clinical trial with the iron chelator Deferiprone in Parkinson's disease
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005673-60 Sponsor Protocol Number: Droxidopa-302 Start Date*: 2009-04-22
    Sponsor Name:Chelsea Therapeutics Inc
    Full Title: A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP WITHDRAWAL-DESIGN STUDY TO ASSESS THE CLINICAL EFFECT OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE ...
    Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (PD, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005310-19 Sponsor Protocol Number: PI-0697-2012 Start Date*: 2013-06-05
    Sponsor Name:FUNDACION PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL_ FPA
    Full Title: Double-blind randomized clinical trial to evaluate the efficacy and safety of levosimendan as preischemic myocardial conditioner in pediatric cardiac surgery
    Medical condition: Children aged 1 month to 14 years in the health area of the province of Granada who will be undergoing heart surgery with a clinical high risk of developing acute heart failure after surgery, treat...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023007-10 Sponsor Protocol Number: TF2010 Start Date*: 2011-03-22
    Sponsor Name:Uppsala university
    Full Title: A neuroscience perspective on anxiety proneness - Sex differences, monoaminergic pathways and treatment response
    Medical condition: Men and women diagnosed with DSM-IV social phobia (social anxiety disorder)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10041242 Social anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015833-66 Sponsor Protocol Number: 50/0811 Start Date*: 2009-01-20
    Sponsor Name:CASA DI CURA PRIVATA S.RAFFAELE - PISANA
    Full Title: Ropinirole 24h prolonged release and motor fluctuations: a study to control the wearing-off induced by dopamine agonists immediate release
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002964-90 Sponsor Protocol Number: 27919 Start Date*: 2011-05-05
    Sponsor Name:Newron Pharmaceuticals SpA
    Full Title: A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathi...
    Medical condition: Idiopathic Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Prematurely Ended) FR (Completed) HU (Completed) ES (Completed) NL (Completed) EE (Completed) AT (Completed) SK (Completed) DE (Completed) GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-000412-27 Sponsor Protocol Number: ARG-CS3-001 Start Date*: 2005-08-22
    Sponsor Name:Arginox Pharmaceuticals, Inc.
    Full Title: A Phase III International Multi-center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition with Tilarginine Acetat...
    Medical condition: It is the intent of the proposed study to further evaluate the safety and efficacy of Tilarginine Acetate Injection as a novel, mortality reducing therapeutic drug for patients with cardiogenic sho...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) HU (Prematurely Ended) AT (Completed) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005838-37 Sponsor Protocol Number: A-38-52030-214 Start Date*: 2008-05-15
    Sponsor Name:Beaufour Ipsen Pharma
    Full Title: A PROSPECTIVE, INTERNATIONAL, MULTI-CENTRIC, OPEN-LABEL STUDY TO ASSESS THE EFFICACY OF AN EXTENDED INJECTION INTERVAL SCHEDULE OF LANREOTIDE AUTOGEL 120 MG IN ACROMEGALIC SUBJECTS WHO ARE BIOCHEMI...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) DK (Completed) NL (Completed) FI (Completed) LV (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-004509-11 Sponsor Protocol Number: dopa_HSP Start Date*: 2005-05-13
    Sponsor Name:University hospital of the University of Ulm
    Full Title: Efficiency and tolerability of L-Dopa in patients with Hereditary Spastic Paraplegia (HSP)
    Medical condition: Hereditary spastic paraplegias (HSP) are a rare neurodegenerative group of disorders characterised by slowly progressive symmetric spastic paraparesis, distal pallhypaesthesia of the lower limbs, a...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001108-35 Sponsor Protocol Number: NRA 6290010 Start Date*: 2006-07-03
    Sponsor Name:Clinic of University of Wuerzburg
    Full Title: CHANGES OF LEFT VENTRICULAR MASS AND CARDIAC FUNCTION IN PATIENTS WITH ACTIVE ACROMEGALY DURING TREATMENT WITH THE GROWTH HORMONE RECEPTOR ANTAGONIST PEGVISOMANT: AN OPEN-LABELLED, PROSPECTIVE STUDY
    Medical condition: Somavert (Pegvisomant) is approved for the treatment of acromegalic patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapy as Somatostatin Ana...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061835 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018720-12 Sponsor Protocol Number: pb01 Start Date*: 2010-04-22
    Sponsor Name:Swedish Pituitary Study group
    Full Title: Behandling med kabergolin hos patienter med ACTH-beroende Cushing´s syndrom (treatment with cabergoline in patients with ACTH-dependent Cushing´s syndrome
    Medical condition: A) Men and women aged 18 to 75 years with hypercortisolism due to ACTH-dependent Cushing's syndrome will be treated in the period between diagnosis and planned surgery or radiation therapy. B) Men...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000833-12 Sponsor Protocol Number: NW-1015/015/III/2003 Start Date*: 2004-12-02
    Sponsor Name:Newron Pharmaceuticals S.p.A.
    Full Title: A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients ...
    Medical condition: Early idiopathic Parkinson’s disease
    Disease: Version SOC Term Classification Code Term Level
    7.0 10013113 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003072-39 Sponsor Protocol Number: NTUH-AADC-011 Start Date*: 2019-10-09
    Sponsor Name:National Taiwan University Hospital
    Full Title: A Clinical Trial for Treatment of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC - An Expansion
    Medical condition: Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-005852-42 Sponsor Protocol Number: CSMS995BIC03 Start Date*: 2007-04-20
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open-label, two-step, multicenter European study to evaluate the efficacy and safety of Sandostatin LAR at High Dose or in combination either with GH-receptor antagonist or dopamine-agonist i...
    Medical condition: acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 05:24:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA